Truist initiated coverage on Infinity Pharmaceutical with a new price target
$INFI
Biotechnology: Pharmaceutical Preparations
Health Care
Truist initiated coverage of Infinity Pharmaceutical with a rating of Buy and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/18/2021 | $9.00 | Buy | HC Wainwright & Co. |
| 8/2/2021 | $6.00 | Neutral → Overweight | JP Morgan |
| 7/28/2021 | $4.00 → $14.00 | Equal-Weight → Overweight | Wells Fargo |
| 7/7/2021 | $7.00 | Buy | B. Riley Securities |
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced a series of actions designed to reduce the Company's burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc. The Company continues to believe, based on the data generated to date, that eganelisib offers a near-term value creation opportunity that would be attractive to potential third-party acquirers. Infinity has advanced eganelisib toward the init
Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI"). At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for the merger with Infinity, nor could MEI obtain approval for an adjournment of the special meeting. In the process o
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the Infinity transaction today, you have the opportunity to participate in the upside potential of a combined company with: a diversified therapeutic pipeline; a team that brings clinical development and regulatory expertise; and the capabilities and resources to develop new oncology therapeutics for the benefi
HC Wainwright & Co. initiated coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $9.00
JP Morgan upgraded Infinity Pharmaceuticals from Neutral to Overweight and set a new price target of $6.00
Wells Fargo upgraded Infinity Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $14.00 from $4.00 previously